Dr Aidan Murphy becomes Ipsen’s new Executive VP, Technical Operations

pharmafile | January 10, 2018 | Appointment | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing appointment, ipsen, pharma 

Dr Aidan Murphy has been named by Ipsen’s new Executive Vice President, Technical Operations, succeeding Jonathan Barnsley who retired at the end of 2017. In addition to his new position, Dr Murphy will also serve on the French biopharmaceutical company’s executive leadership team.

Dr Murphy has worked in the pharmaceutical and biotechnology industry for more than 25 years, and has served at Ipsen since 2007, boasting a range of manufacturing leadership roles across a number of countries throughout his career. Dr Murphy has held the role of Senior Vice President, Biologics Development and Manufacturing at Ipsen since 2014, and has previously led manufacturing sites in Tianjin in China, Dublin in Ireland, and Wrexham in England during his time with the company.

David Meek, CEO of Ipsen, commented on Dr Murphy’s appointment, remarking: “It is my great pleasure to welcome Aidan to Ipsen’s executive leadership team. He brings outstanding manufacturing leadership experience and an international perspective, having worked across multiple geographies both prior to and during his career with Ipsen. Aidan has played an instrumental role in the transformation of Ipsen Technical Operations in recent years, and the continuity of leadership he brings will be critical as we continue our development as a leading global biopharma company.”

Advertisement

Related Content

Pharma sees climate disruption as growing supply-chain risk

Nine in ten pharmaceutical companies across the UK and G7 countries expect climate-related disruption to …

AI in pharma: From lab development to patient impact

In the decade to 2025, AI use in vaccine development has increased markedly but is …

Phase 3 trials support expanded use of Dysport for migraine prevention

Ipsen has reported positive topline results from its phase 3 BEOND clinical programme evaluating Dysport …

The Gateway to Local Adoption Series

Latest content